UY33542A - Uso de teriflunomida para tratar la esclerosis múltiple - Google Patents

Uso de teriflunomida para tratar la esclerosis múltiple

Info

Publication number
UY33542A
UY33542A UY0001033542A UY33542A UY33542A UY 33542 A UY33542 A UY 33542A UY 0001033542 A UY0001033542 A UY 0001033542A UY 33542 A UY33542 A UY 33542A UY 33542 A UY33542 A UY 33542A
Authority
UY
Uruguay
Prior art keywords
teriflunomide
multiple sclerosis
treat multiple
treat
treatment
Prior art date
Application number
UY0001033542A
Other languages
English (en)
Inventor
Rocklin Ross
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of UY33542A publication Critical patent/UY33542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Esta invención se refiere al uso de teriflunomida para el tratamiento de la Esclerosis Múltiple(EM) y para tratar los riesgos asociados con el uso de teriflunomida.
UY0001033542A 2010-08-02 2011-08-02 Uso de teriflunomida para tratar la esclerosis múltiple UY33542A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36977910P 2010-08-02 2010-08-02
US36978010P 2010-08-02 2010-08-02
US38937510P 2010-10-04 2010-10-04
US201061424717P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
UY33542A true UY33542A (es) 2012-02-29

Family

ID=45559773

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033542A UY33542A (es) 2010-08-02 2011-08-02 Uso de teriflunomida para tratar la esclerosis múltiple

Country Status (4)

Country Link
EP (1) EP2600861A1 (es)
AR (1) AR082436A1 (es)
UY (1) UY33542A (es)
WO (1) WO2012018704A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
WO2021204994A1 (en) * 2020-04-09 2021-10-14 Novartis Ag Ofatumumab for treating ms while maintaining serum igg

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Also Published As

Publication number Publication date
AR082436A1 (es) 2012-12-05
EP2600861A1 (en) 2013-06-12
WO2012018704A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
CR20130550A (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
ECSP15026557A (es) Compuestos y sus métodos de empleo
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CL2012003385A1 (es) Tratamiento para la incontinencia.
CR20130045A (es) Compuestos terapéuticos
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
AR089993A1 (es) Macrociclos peptidomimeticos
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2013000675A1 (es) Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
DOP2014000098A (es) 2-tiopirimidinonas
IN2014CN04014A (es)
CO6410315A2 (es) Nuevos anticuerpos anti-alfa5beta1 y sus usos
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34315A (es) ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?
IN2015DN01524A (es)
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
UY33542A (es) Uso de teriflunomida para tratar la esclerosis múltiple
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
CR20150159A (es) Derivados oxazolidinona 3,4-disustituidos y su uso como inhibidores de potasio calcio activado